Dominique Costantini, Co-Founder of OSE Pharma, Invited to « Bpifrance Inno Génération » in Paris, May 25 & 26, 2016

PARIS & NANTES, France--()--Regulatory News:

OSE Pharma SA (ISIN: FR0012127173; Ticker: OSE) (Paris:OSE), an immuno-oncology company, and Effimune, a biotech company specialized in immune regulation, today announce that Dominique Costantini, Chief Executive Officer of OSE Pharma, will be participating in a round table dedicated to innovative companies in the field of immunotherapy to be held at the 2nd edition of “Bpifrance Inno Generation” (May 25 - 26, 2016, AccordHotels Arena, Paris).

This event is focused on entrepreneurship and innovation and a key roundtable discussion will be dedicated to innovation in the field of immunotherapy (on May 26, 2016, from 10:45am to 12:00pm). Dominique Costantini, Medical Doctor and Immunologist, will share her know-how and experience as an entrepreneur who has succeeded in building biotechnology companies in the areas of oncology, immuno-oncology and immunotherapy.

Dominique Costantini is co-founder and CEO of OSE Pharma, an immuno-oncology company developing a specific immunotherapy activating T lymphocytes, currently in a registration Phase 3 study.

OSE Pharma and Effimune, a biotech company specialized in immune regulation for applications in transplantation, autoimmunity and cancer immunotherapy, are intending to merge to create OSE Immunotherapeutics, and become a leader in the field of activation and regulation immunotherapy. Subject to and after completion of the merger end of May 2016, Dominique Costantini will become CEO of the new company.

Maryvonne Hiance, co-founder of Effimune, will become Vice Chairman of the Board of Directors of OSE Immunotherapeutics. She was previously awarded the 2015 « Trophée de l’Entrepreneur Femme en Santé », a prize awarded to a woman entrepreneur in the health area, by France Biotech, a French association of entrepreneurs in life sciences.

This event will be broadcasted on Bpifrance and on the partner digital media of Bpifrance Inno Generation.

« Bpifrance Inno Génération »
“Bpi Inno Generation” will bring together about 25,000 entrepreneurs from all over France and from all areas of activity. Very small, small, middle and intermediate-sized enterprises, start-ups, large groups, financiers and student entrepreneurs will meet during this event dedicated to business. “Bpi Inno Generation” aims to enable each group to find points of growth, partners for development, to create value and build alliances.

ABOUT THE MERGER BETWEEN OSE PHARMA AND EFFIMUNE

On February 24, 2016, OSE Pharma and Effimune announced a proposed merger to create OSE Immunotherapeutics, a significant immunotherapy player. The terms of the merger will be submitted for approval to the shareholders of the two companies during the next General Meetings: on May 30, 2016 for Effimune and on May 31, 2016 for OSE Pharma.

The objective of the merger is to create a new international enterprise that offers innovative immunotherapies based on the activation or regulation of the immune system. This new generation of products is optimized to better target key receptors of the activation or regulation of immune response and allow a durable therapeutic effect. The new company will benefit from a balanced portfolio that would open up major avenues to growth and have a financial visibility of about two years to advance its projects toward greater attractiveness.

OSE PHARMA is a biotechnology company that designs and develops cancer immunotherapy treatments aimed at re-educating the immune system to fight cancer while preserving patients’ quality of life. The Company is conducting a Phase 3 registration trial in Europe and the U.S. for its lead product, Tedopi®, in the treatment of NSCLC.

OSE Pharma is listed on Euronext Paris (ISIN: FR0012127173; Mnemo: OSE).

For more information, please visit www.osepharma.com

EFFIMUNE is a biotech company specialized in immune regulation for applications in transplantation, autoimmunity and cancer immunotherapy. The originality of Effimune’s therapeutic strategy, compared to conventional immunosuppression, is the modification in the balance between effector and regulatory immune cells. The biological drugs Effimune develops are aimed at restoring the natural balance of these cells by targeting the molecular checkpoint.

The expertise of the company lies in its ability to identify new therapeutic targets and develop effective biomolecules for the pharmaceutical industry by guaranteeing the manufacture of pilot and clinical batches and by validating preclinical and clinical proofs of concept.

For more information, please visit: www.effimune.com

Forward-looking statements

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE PHARMA. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE PHARMA’s management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

Forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import.

Although the OSE PHARMA’s management believes that the forward-looking statements and information are reasonable, the OSE PHARMA’s shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE PHARMA. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE PHARMA with the AMF. Such forward-looking statements are not guarantees of future performance.

This press release includes only summary information and should be read with the OSE PHARMA Reference Document filed with the AMF on 12 June 2015 under the number R.15-051, the consolidated financial statements and the management report for the fiscal year 2015, as well as the Merger Document registered with the AMF on 26 April 2016 under number E.16-026, all available on the OSE PHARMA website.

OSE PHARMA undertakes no obligation to update any forward-looking statements except what would be required by applicable laws and regulations.

Contacts

OSE Pharma SA
Dominique Costantini, CEO
dominique.costantini@osepharma.com
Mob : +33 6 13 20 77 49
or
Alexis Peyroles, CFO & BD
Alexis.peyroles@osepharma.com
Mob : +33 6 11 51 19 77
or
Effimune
Maryvonne Hiance, Chairman
Tel : +33 (0) 240 412 834
Mobile : 33 (0) 680 060 183
mhiance@effimune.com
or
Media contacts
Citigate Dewe Rogerson
Laurence Bault
laurence.bault@citigate.fr
+33 1 53 32 84 78
or
Alize RP
Florence Portejoie & Caroline Carmagnol
osepharma@alizerp.com
+33 6 47 38 90 04
or
Consilium Strategic Communications
Chris Gardner / Matthew Neal /
Hendrik Thys
OSEPharma@consilium-comms.com
+44 (0) 20 3709 5700
or
Rx Communications Group, LLC
Melody Carey
mcarey@rxir.com
+ 1 917-322-2571
or
Acorelis
Gilles Petitot
gilles.petitot@acorelis.com
+33 (0) 620 27 65 94

Contacts

OSE Pharma SA
Dominique Costantini, CEO
dominique.costantini@osepharma.com
Mob : +33 6 13 20 77 49
or
Alexis Peyroles, CFO & BD
Alexis.peyroles@osepharma.com
Mob : +33 6 11 51 19 77
or
Effimune
Maryvonne Hiance, Chairman
Tel : +33 (0) 240 412 834
Mobile : 33 (0) 680 060 183
mhiance@effimune.com
or
Media contacts
Citigate Dewe Rogerson
Laurence Bault
laurence.bault@citigate.fr
+33 1 53 32 84 78
or
Alize RP
Florence Portejoie & Caroline Carmagnol
osepharma@alizerp.com
+33 6 47 38 90 04
or
Consilium Strategic Communications
Chris Gardner / Matthew Neal /
Hendrik Thys
OSEPharma@consilium-comms.com
+44 (0) 20 3709 5700
or
Rx Communications Group, LLC
Melody Carey
mcarey@rxir.com
+ 1 917-322-2571
or
Acorelis
Gilles Petitot
gilles.petitot@acorelis.com
+33 (0) 620 27 65 94